Bulletin
Investor Alert

New York Markets Close in:

Annovis Bio Inc.

NYS: ANVS

GO
/marketstate/country/us

Market open

 --Real time quotes

Feb 6, 2023, 1:32 p.m.

/zigman2/quotes/216213707/composite

$

20.30

Change

+0.96 +4.97%

Volume

Volume 62,416

Real time quotes

/zigman2/quotes/216213707/composite

Previous close

$ 19.34

$ 20.30

Change

+0.96 +4.97%

Day low

Day high

$19.00

$20.72

Open

52 week low

52 week high

$8.39

$23.91

Open

Michael B. Hoffman

Michael B. Hoffman is an entrepreneur and businessperson who founded Northern Genesis Acquisition Corp., Northern Genesis Acquisition Corp. II, Northern Genesis Acquisition Corp. III and Stone Capital Partners LLC and who has been the head of 5 different companies. Presently, Michael B. Hoffman holds the position of Chairman for Annovis Bio, Inc., President & Chief Executive Officer of Northern Genesis Acquisition Corp. III and President of Northern Genesis Acquisition Corp. Mr. Hoffman is also Member-Executive Council at International Institute For Nanotechnology, Partner at Stone Capital Partners LLC and Managing Director at Northern Genesis Climate Solutions Corp. and on the board of 12 other companies.

In his past career Mr. Hoffman held the position of Chairman at Onconova Therapeutics, Inc., Partner at Riverstone Holdings LLC and Partner at Riverstone Investment Group LLC (a subsidiary of Riverstone Holdings LLC), Senior Managing Director at The Blackstone Group, Inc. (Illinois), President of Northern Genesis Acquisition Corp. II, Managing Director, Head-Mergers & Acquisitions at Smith Barney Harris Upham & Co., Inc. and Head-Mergers & Acquisitions at Smith Barney & Co., Inc.

Mr. Hoffman received a graduate degree and an undergraduate degree from Northwestern University and an MBA from Harvard Business School.

Transactions

Date Shares Transaction Value
01/04/2022 90   Derivative/Non-derivative trans. at $19.78 per share. 1,781
01/04/2022 7,142   Derivative/Non-derivative trans. at $0.25 per share. 1,785
01/04/2022 6,658   Derivative/Non-derivative trans. at $19.78 per share. 131,696
01/04/2022 30,000   Derivative/Non-derivative trans. at $4.39 per share. 131,700
01/31/2020 55,884   Derivative/Non-derivative trans. at $4.8 per share. 268,243
01/31/2020 1,137,942   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 158,730   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 33,333   Acquisition at $6 per share. 199,998

Officers and Executives

Dr. Maria-Luisa Maccecchini
President, Chief Executive Officer & Director
Mr. Henry Hagopian
Dr. Cheng Fang
Senior Vice President-Research & Development
Ms. Eve M. Damiano
Senior Vice President-Regulatory Operations
Mr. Michael B. Hoffman
Chairman
Mr. Reid S. McCarthy
Independent Director
Dr. Claudine E. Bruck
Independent Director
Mr. Mark White
Independent Director
Link to MarketWatch's Slice.